<DOC>
	<DOCNO>NCT01032837</DOCNO>
	<brief_summary>This randomize , double-blind , multi-center study Tamiflu ( Oseltamivir ) evaluate efficacy viral activity , effectiveness resolve disease symptom , safety tolerability patient influenza . Patients ( H1N1 ) 2009 influenza strain influenza A eligible study . Patients randomize one four treatment regimen . Patients receive oral dos either 75 mg ( adult ) 150 mg ( adult ) study drug twice daily 5 10 consecutive day . The dose body weight-adjusted pediatric patient .</brief_summary>
	<brief_title>A Study Tamiflu ( Oseltamivir ) Treatment Influenza With Focus ( H1N1 ) 2009 Flu Strain</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Pediatric , adolescent adult patient &gt; /=1 year age Fever &gt; /=37.8 degrees C least one respiratory symptom ( cough , coryza , sore throat , rhinitis ) Positive rapid diagnostic test pandemic ( H1N1 ) 2009 virus influenza A 24 hour prior first dose study drug &lt; /=96 hour onset influenzalike illness first dose oseltamivir Currently receive form renal replacement therapy include hemodialysis , peritoneal dialysis , hemofiltration History chronic renal failure clinical suspicion renal failure baseline Clinical evidence hepatic compensation time randomization Known HIV infection Vaccination live attenuate influenza vaccine ( LAIV ) two week prior first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>